Trial Profile
A Double-blind, Placebo-controlled, Randomized Efficacy and Safety Study of Keppra Extended Release Formulation - XR Once Daily as add-on Therapy in Subjects From 12 to 70 Years With Refractory Epilepsy Suffering From Partial Onset Seizures
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jul 2020
Price :
$35
*
At a glance
- Drugs Levetiracetam (Primary)
- Indications Epilepsy; Partial epilepsies
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors UCB
- 12 Jul 2011 Actual end date changed from May 2007 to Jul 2007 as reported by European Clinical Trials Database.
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database record, EudraCT2006-000987-10).
- 05 Dec 2008 Results published in Epilepsia.